Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-10-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartanginacardiactherapycolorectal
  Phrases that lowered it: malepatientspharmacokineticsthe studyadequate contraception
• Sponsor's past termination rate: 20.9% (raises risk) · Sponsor's track record
• Minimum age: 21 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Maximum age: 99 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.8% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Primary purpose: basic science (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 5839 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 73.1% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients NCT01183494 · started 2009 · scored riskier than 76% of active trials completed
• Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors NCT03295084 · started 2015 · scored riskier than 52% of active trials completed
• AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer NCT00535353 · started 2008 · scored riskier than 49% of active trials completed
• Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin NCT00861328 · started 2008 · scored riskier than 41% of active trials completed
• CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin NCT00969033 · started 2009 · scored riskier than 90% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.